Research Progress on Relation Between CD47 and Immunotherapy on Lymphoma
CD47 is a member of the immunoglobulin superfamily. It is expressed on various cells and tissues of human, but it is more expressed on tumor cells, especially in various hematopoietic tumors. The combination of CD47 expressed on tumor cells with signal regulator protein α (SIRPα) on macrophages inhi...
Main Authors: | LUO Yiyang, FENG Xiaoli |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2021-08-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://www.zlfzyj.com/EN/abstract/abstract9879.shtml |
Similar Items
-
Research Progress of CD47-SIRPα Signaling Axis as An Innate Immune Checkpoint in Cancer
by: ZHA Li, et al.
Published: (2018-08-01) -
Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
by: Lu Q, et al.
Published: (2020-09-01) -
Stimulation of Glioblastoma Proliferation by Macrophages Through CD47/SIRPα
by: Badham, Katelyn
Published: (2017) -
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
by: Wenting Zhang, et al.
Published: (2020-01-01) -
Luteolin promotes macrophage-mediated phagocytosis by inhibiting CD47 pyroglutamation
by: Zhiqiang Li, et al.
Published: (2021-08-01)